RICHMOND, British Columbia, June 2, 2011 (GLOBE NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today that it has contracted the services of CaroLink Science Solutions to help expedite the FDA approval of its RECAF™ cancer marker test and to compile the large amount of data acquired by BioCurex for publication in peer-reviewed medical journals. Unlike other notable cancer markers that only detect the presence of a specific cancer type (CEA for colon cancer and PSA for prostate cancer), RECAF is found on most types of cancer and, therefore, could have a much broader use than most other cancer markers currently under development or in use today. Moreover, unlike existing cancer markers, RECAF has been shown to detect early stages of breast and prostate cancers when the likelihood of a cure is the highest.
